Türk Nöroşirürji Dergisi 2019 , Vol 29 , Num 3
Diffuse Glioma
Serhat PUSAT1,Abidin Murat GEYIK2
1Sağlık Bilimleri Üniversitesi, Sultan Abdulhamid Eğitim ve Araştırma Hastanesi, Beyin ve Sinir Cerrahisi Kliniği, İstanbul, Türkiye
2Gaziantep Üniversitesi, Tıp Fakültesi, Beyin ve Sinir Cerrahisi Anabilim Dalı, Gaziantep, Türkiye
Gliomas constitute 30% of primary central nervous system tumors. The incidence in adults is 26/100,000. They are often seen in the second and third decades. This neoplasm is most often diagnosed because of seizures, even though incidental discovery is becoming increasingly frequent. Gliomas progresses continuously and invade the connectome by migrating along the white matter fibres. The main targets in glioma treatment are maximum tissue resection, focal deficit and epilepsy control, and to extend the survival. In relevant studies, the genomic structure of the tumor has been revealed. The IDH (IsocitrateDehydrogenase) mutation and 1p19q deletion genetic diversities are most commonly used for treatment planning.

IDH mutation and 1p19q deletion are indicative of a good prognosis for diffuse gliomas. The presence of this genomic sequence has a major effect on the survival. Anahtar Kelimeler : Glioma, Surgery, Genome